Multi-Agent Workflow for Oncology Target and Combination Therapy Discovery

Manual analysis of tumor genomics, synthetic lethality, and immune infiltration patterns is a sequential, expert-limited bottleneck. An orchestrated agent workflow runs these analyses in parallel, continuously ingesting new public and internal data. By automating hypothesis generation and prioritization, the first list of novel, mechanistically rational targets is delivered in weeks, not months, allowing your team to initiate validation campaigns sooner.

Manually predicting drug synergy and overlapping toxicity is error-prone and limited to known pairs. Specialized agents model drug interaction networks, predict polypharmacology, and assess toxicity profile overlaps using mechanistic and historical data. This systematic, AI-driven screening flags high-risk antagonistic or toxic combinations early, preventing costly late-stage failures in preclinical development and focusing resources on regimens with a stronger safety and efficacy rationale.

Traditional discovery often prioritizes targets or compounds based on narrow, single-dimensional data (e.g., potency alone). This workflow forces a multi-parameter optimization (MPO) from day one, scoring candidates on genomic evidence, druggability, synergy potential, and toxicity. The result is a pipeline built on a defensible, data-rich mechanistic hypothesis, which strengthens regulatory submissions and increases the probability of clinical success.

Uncoordinated virtual screening and wet-lab experiments waste cloud compute and lab resources on low-probability candidates. The workflow acts as an intelligent gatekeeper, using cheaper in silico agents to rigorously triage millions of possibilities down to a focused, high-value set for expensive experimental validation. This precise funneling reduces HTS and in vivo study costs by ensuring every assay dollar is spent on candidates that have already passed multiple AI-driven filters.

Ad-hoc analyses and spreadsheet tracking lack reproducibility and scale. A custom-built workflow on frameworks like LangGraph or CrewAI provides a version-controlled, observable architecture. Every agent's decision, data source, and approval gate is logged, creating a complete audit trail for internal review and regulatory inquiries. This transforms discovery from a black-box art into a scalable, governed engineering process that can be replicated across multiple oncology programs.

When new clinical or competitive data emerges, manually re-evaluating an entire portfolio is impractical. An agentic workflow with continuous data ingestion can automatically re-score targets and combinations against new evidence. This allows for dynamic portfolio strategy, enabling your team to deprioritize assets with weakened rationale and double down on emerging opportunities with agility, protecting R&D investment from dead ends.

This agent automates the initial bottleneck of identifying novel, druggable oncology targets. It ingests multi-omics data (genomic, transcriptomic, proteomic) from public repositories (e.g., TCGA, DepMap) and internal cohorts to perform differential expression analysis, pathway enrichment, and network propagation. Its core function is to predict synthetic lethal interactions—where targeting a gene is lethal only in the context of a specific tumor mutation (e.g., PARP inhibitors in BRCA-mutated cancers). By systematically mining genetic dependencies, it generates ranked target hypotheses with a mechanistic rationale, reducing target identification from months to weeks.

This agent automates the analysis of tumor immune infiltration patterns from histopathology images and RNA-seq data to identify immunomodulatory targets. It classifies tumor immune phenotypes (e.g., hot, cold, excluded), quantifies cell populations (T-cells, macrophages), and evaluates checkpoint expression. For immuno-oncology programs, it predicts which targets (e.g., novel checkpoints, cytokine receptors) are most likely to convert 'cold' tumors to 'hot,' thereby de-risking combination strategies with existing immunotherapies. It integrates with digital pathology systems and generates structured reports for the project team.

This agent automates the high-complexity task of predicting rational drug combinations. Given a set of candidate compounds (internal or approved), it constructs a drug-target-pathway network using knowledge graphs (e.g., STITCH, DrugBank). It then applies mechanistic models and ML-trained synergy predictors to score pairings for additive or synergistic effects, while flagging potential antagonism. This moves combination discovery beyond empirical screening to a hypothesis-driven process, enabling the prioritization of a shortlist of high-potential regimens for experimental validation in a 3D co-culture or in vivo model.

A critical gatekeeper agent that automates the prediction of overlapping toxicity profiles for proposed drug combinations. It queries internal safety databases and external sources (e.g., FDA labels, preclinical studies) to profile each compound's known organ toxicities (hepatic, cardiac, renal). Using ontology mapping, it identifies potentiating risks—where combined mechanisms could exacerbate a specific adverse event (e.g., dual QTc prolongation). This agent prevents the advancement of high-risk combinations into costly preclinical studies, directly addressing a major cause of late-stage combination therapy failure.

This orchestration agent automates the final business and scientific decision-making by evaluating discovery outputs against a Target Product Profile (TPP) and portfolio strategy. It aggregates data from all upstream agents (target rank, synergy score, toxicity flags) into a unified dashboard. It applies configurable, weighted scoring rubrics to rank single agents and combinations, models their projected development cost and probability of success, and simulates portfolio impact. It ensures governance by requiring human-in-the-loop approval before candidates are promoted, creating a defensible audit trail for pipeline reviews.

This infrastructure agent automates the data flow between the AI workflow and enterprise R&D systems. It handles the bidirectional sync with Electronic Lab Notebooks (ELNs) and Laboratory Information Management Systems (LIMS), pushing agent-generated hypotheses (e.g., a target list) as experimental work orders and pulling back validation results (e.g., IC50 data) to retrain predictive models. Built on frameworks like LangGraph or Prefect, it manages execution queues, handles API exceptions, and maintains a full data lineage. This component is essential for closing the Design-Make-Test-Analyze (DMTA) loop and operationalizing the discovery pipeline.